Results 191 to 200 of about 24,933,173 (248)

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

Cancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub

Cancer Science, EarlyView.
PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source